Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts

{
  "signal_id": "24dba2f5-4c44-b7d7-89c3-987dc0ac8ad2",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-09-05T10:18:45+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.easternprogress.com/eli-lilly-to-expand-vaccine-pipeline-with-three-biotech-buyouts/article_fdb2cc74-4b73-5577-a1da-446b0ae52b24.html",
    "title": "Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts - Eastern Progress",
    "excerpt": "Eli Lilly LLY announced that it has agreed to acquire three privately held biotech companies as it looks to expand its pipeline in vaccines and infectious diseases. The transactions, valued at about $3.83 billion in total, mark one of the company’s biggest pushes outside its core therapeutic areas of obesity, diabetes and oncology. Lilly plans to acquire Curevo, LimmaTech Biologics and Vaccine Company, each of which brings vaccine candidates and platform technologies targeting infectious diseases with significant unmet need. The company is acquiring Curevo in a deal valued at up to $1.5 billion. This deal centers on Curevo’s lead asset, amezosvatein, a phase III-ready vaccine candidate for the prevention of shingles in adults. Based on encouraging data from a mid-stage study, Lilly believes the program could offer strong efficacy with improved tolerability compared with existing shingles vaccines. Lilly is also acquiring LimmaTech Biologics in a deal valued at up to $780 million. Through the acquisition, Lilly will gain access to a proprietary vaccine platform focused on preventing bacterial infections and addressing antimicrobial resistance. LimmaTech’s pipeline includes multiple vaccine candidates, including lead program LTB-SA7, which is in early-stage development for Staphylococcus aureus, the leading cause of surgical-site infections. The company is further acquiring the...",
    "summary": "Eli Lilly and Company is acquiring LimmaTech Biologics for up to $780 million to gain access to its proprietary vaccine platform.",
    "planning": true,
    "image_url": "https://bloximages.newyork1.vip.townnews.com/easternprogress.com/content/tncms/custom/image/196deb6e-516f-11ee-9335-6394f0ed519c.png?resize=600%2C600",
    "confidence": 0.95,
    "published_at": "2026-09-05T10:18:45Z",
    "article_sentence": "Lilly is also acquiring LimmaTech Biologics in a deal valued at up to $780 million.",
    "amount_normalized": 780000000,
    "related_company_name": "LimmaTech Biologics",
    "related_company_domain": "lmtbio.com"
  }
}

curl https://signals.autobound.ai/v1/signals/24dba2f5-4c44-b7d7-89c3-987dc0ac8ad2 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'